Degron Therapeutics Inc. has entered into a collaboration and exclusive license agreement with Takeda Pharmaceutical Co. Ltd. to discover and develop novel molecular glue degraders for multiple targets in oncology, neuroscience and inflammation.
Achilles Therapeutics plc has established a research collaboration with Arcturus Therapeutics Holdings Inc. to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines targeting clonal neoantigens.
Spybiotech Ltd. has entered into a sponsored research agreement with the University of Oxford for the development of a vaccine against Epstein-Barr virus (EBV).
Evergreen Theragnostics Inc. has entered into a collaboration and licensing agreement with the Medical University of Innsbruck (MUI) to advance the development of novel radiopharmaceuticals.
Totus Medicines Inc. has entered into a multi-target research collaboration with Eli Lilly & Co. to discover small-molecule drug candidates against undisclosed targets in different therapeutic areas.
Lift Biosciences Ltd. has been awarded a grant of over £1 million (US$1.3 million) from Innovate UK that will fund a collaboration between Lift and researchers at the University of Cambridge.
A collaboration between Plaquetec Ltd. and a lab at the Babraham Institute has demonstrated the druggability of a pro-inflammatory protein discovered by Plaquetec.
Centogene NV and Evotec SE have announced the discovery of a new small molecule with potential to treat patients with type 2 and type 3 Gaucher disease, or neuronopathic Gaucher disease.
Fogpharma Inc. and Artbio Inc. have established a collaboration to co-develop a new class of α-radioligand therapeutics to maximize efficacy for patients with multiple types of cancer.
RSS
